Clinical Trials

Inclusion Criteria

• Must consent to provide an archived tumor specimen
• Must have histologically or cytologically confirmed advanced solid tumor for recurrent or metastatic disease
• At the time of day 1 of the study, central nervous system (CNS) metastases must have been treated and must be asymptomatic
• Willing to provide pretreatment and on-treatment biopsies
• Has adequate organ function
• Females of childbearing potential and nonsterilized males who are sexually active must use effective methods of contraception

Exclusion Criteria

• A known allergic reaction to any component of MEDI1873
• Concurrent enrollment in another clinical study, unless it is an observational clinical study or the follow-up period of an interventional study
• Receiving any anticancer therapy within 4 weeks prior to the first dose of MEDI1873 or in the case of mAbs, 6 weeks prior to the first dose of MEDI1873
• Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment
• Receiving a live, attenuated vaccine within 28 days prior to the first dose of investigational product
• Unresolved toxicities from prior anticancer therapy
• Any condition that, in the opinion of the investigator or sponsor, would interfere with evaluation of the investigational product